Zacks Research Upgrades Beauty Health (NASDAQ:SKIN) to “Strong-Buy”

Beauty Health (NASDAQ:SKIN) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

A number of other equities analysts also recently issued reports on SKIN. Wall Street Zen upgraded shares of Beauty Health from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Beauty Health in a report on Wednesday, October 8th. Roth Capital assumed coverage on shares of Beauty Health in a research note on Friday, September 19th. They issued a “buy” rating and a $3.50 price objective on the stock. Stifel Nicolaus increased their price objective on shares of Beauty Health from $3.00 to $4.00 and gave the company a “hold” rating in a research note on Friday, August 1st. Finally, Cowen reissued a “hold” rating on shares of Beauty Health in a research note on Monday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Beauty Health presently has an average rating of “Hold” and an average target price of $2.81.

Beauty Health Stock Performance

Shares of SKIN opened at $1.33 on Tuesday. The company has a 50-day simple moving average of $1.98 and a 200-day simple moving average of $1.71. The company has a quick ratio of 4.15, a current ratio of 5.15 and a debt-to-equity ratio of 4.91. The company has a market capitalization of $168.67 million, a PE ratio of -4.75 and a beta of 1.21. Beauty Health has a 52-week low of $0.78 and a 52-week high of $2.69.

Beauty Health (NASDAQ:SKIN) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. The business had revenue of $78.20 million during the quarter, compared to the consensus estimate of $74.67 million. Beauty Health had a negative net margin of 6.13% and a negative return on equity of 32.82%. Beauty Health has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts predict that Beauty Health will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Beauty Health

Several hedge funds have recently modified their holdings of the company. Mirabella Financial Services LLP boosted its stake in shares of Beauty Health by 5.0% during the 2nd quarter. Mirabella Financial Services LLP now owns 12,861,549 shares of the company’s stock worth $24,566,000 after purchasing an additional 614,602 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Beauty Health by 27.5% during the 2nd quarter. Geode Capital Management LLC now owns 2,302,784 shares of the company’s stock worth $4,399,000 after acquiring an additional 496,963 shares during the period. Soleus Capital Management L.P. purchased a new position in shares of Beauty Health during the 2nd quarter worth about $1,910,000. Prescott Group Capital Management L.L.C. lifted its holdings in shares of Beauty Health by 29.2% during the 2nd quarter. Prescott Group Capital Management L.L.C. now owns 835,939 shares of the company’s stock worth $1,597,000 after acquiring an additional 189,141 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Beauty Health by 5.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 665,706 shares of the company’s stock worth $892,000 after acquiring an additional 31,880 shares during the period. 93.26% of the stock is owned by institutional investors and hedge funds.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.